Evidence map›Paper›PMID 41257273›Full record

ArticleWorld journal of gastroenterology2025

Sirolimus and gastrointestinal angiodysplasia: Can an established agent change the way gastrointestinal bleeding is managed?

Robert Sean O'Neill, Jeyvin Nandakumaran, Robert Feller

Abstract readEditorial
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Robert Sean O'NeillDepartment of Gastroenterology and Hepatology, Campbelltown Hospital, Campbelltown 2560, New South Wales, Australia.
Jeyvin NandakumaranDepartment of Gastroenterology and Hepatology, Campbelltown Hospital, Campbelltown 2560, New South Wales, Australia.
Robert FellerDepartment of Gastroenterology and Hepatology, St Vincent's Hospital, Sydney 2010, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal angiodysplasia (GIAD) is a common, acquired, vascular abnormality in the gastrointestinal tract that is commonly implicated in bleeding. Sirolimus, also known as rapamycin, is a mammalian target of rapamycin pathway inhibitor that has shown significant potential in inhibiting abnormal angiogenesis that has demonstrated efficacy in inhibiting abnormal blood vessel formation in the skin, cornea, and tumors. Sun

Indexed as

AngiodysplasiaGastrointestinal HemorrhageMTOR InhibitorsSirolimusHumansTreatment OutcomeMTOR InhibitorsSirolimusAngiodysplasiaBleedingGastroenterologyGastrointestinal bleedingSirolimus

Identifiers

PMID41257273
PMCPMC12620826

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.